Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mary Long

Internal Medicine Natchitoches, LA Medical Doctor

NPI 1972500221 CMS profile 761348

114 E 5Th St, Natchitoches, LA 71457

Open in the dashboard

General payments

$5,892

356 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mary Long of Natchitoches, LA is reported in the CMS Open Payments database as having received $5,892 across 356 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $834 45
2024 General $1,041 53
2023 General $820 49
2022 General $614 38
2021 General $720 48
2020 General $853 58
2019 General $1,011 65

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mary Long
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Mary Long were reported at $834. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Mary Long Internal Medicine median Middle half National median
2019 $1,011 $159 $48–$570 $163
2020 $853 $119 $33–$402 $114
2021 $720 $135 $37–$521 $132
2022 $614 $141 $42–$496 $149
2023 $820 $149 $45–$519 $160
2024 $1,041 $154 $47–$537 $164
2025 $834 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $986 54 payments
  2. Novo Nordisk Inc $955 61 payments
  3. Lilly USA, LLC $906 60 payments
  4. Amgen Inc. $506 26 payments
  5. GlaxoSmithKline, LLC. $394 22 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $343 23 payments
  7. AbbVie, Inc. $256 16 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $199 14 payments
  9. Esperion Therapeutics, Inc. $193 12 payments
  10. Abbott Laboratories $188 11 payments
  11. Other $966 57 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,886 355 payments
  2. Education $6 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $785 51 payments
  2. FARXIGA $725 40 payments
  3. RYBELSUS $626 42 payments
  4. TRULICITY $523 36 payments
  5. MOUNJARO $456 27 payments
  6. JARDIANCE $416 31 payments
  7. TRELEGY ELLIPTA $307 17 payments
  8. EVENITY $266 11 payments
  9. VRAYLAR $256 16 payments
  10. ZEPBOUND $250 15 payments
  11. Other $3,630 223 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 127 drugs

Part D claims

7,231

Median for Internal Medicine: 777

Drug cost

$879,584

Median for Internal Medicine: $73,373

Branded share of claims

26.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 133 $176,719
Jardiance Empagliflozin Brand 133 $132,066
Eliquis Apixaban Brand 107 $63,830
Farxiga Dapagliflozin Propanediol Brand 68 $62,228
Ozempic Semaglutide Brand 51 $61,487
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 55 $49,162
Rybelsus Semaglutide Brand 41 $44,938
Trulicity Dulaglutide Brand 31 $29,852
Januvia Sitagliptin Phosphate Brand 32 $24,969
Linzess Linaclotide Brand 31 $24,456

The 10 drugs with the highest cost, of 127 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$129,366

Of which drugs: $2,092

Medicare patients

286

Average age 77

Services billed

2,012

205 women, 81 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Diabetes 42%
Ischemic heart disease 26%
Heart failure 25%
Osteoporosis 24%
Chronic kidney disease 23%
Atrial fibrillation 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent, 0.5 ml dosage 90658 Office 87 87 $1,864
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 32 40 $177
Injection, ceftriaxone sodium, per 250 mg J0696 Office 25 34 $10

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EVENITY
  • Amgen Inc. $146
$146 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $97
$97 68 —
MOUNJARO
  • Lilly USA, LLC $83
$83 133 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $62
  • Lilly USA, LLC $18
$81 133 —
NEXLETOL
  • Esperion Therapeutics, Inc. $65
$65 16 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

356 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record